The role of the 'innovative therapies for children with cancer' (ITCC) European consortium

Cancer Treatment Reviews

Volumn 36, Issue 4, 2010, Pages 328-334

  Zwaan, C Michel ^a,g   Kearns, Pamela ^b,g   Caron, Huib ^c,g   Verschuur, Arnauld ^c,g   Riccardi, Riccardo ^d,g   Boos, Joachim ^e,g   Doz, Francois ^f,g   Geoerger, Birgit ^d,g   Morland, Bruce ^b,g   Vassal, Gilles ^d,g  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f INSTITUT CURIE   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Children; Drug development; In vitro testing; ITCC; Pediatric regulation; Phase I studies; Prognosis; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; EPRATUZUMAB; IMATINIB; INSULIN LIKE GROWTH FACTOR RECEPTOR INHIBITOR; NELARABINE; RETINOIC ACID; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; DRUG BIOAVAILABILITY; DRUG FORMULATION; EPENDYMOMA; EUROPE; EXPERIMENTAL THERAPY; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HUMAN; LAW; LYMPHOMA; MEDULLOBLASTOMA; MYELOID LEUKEMIA; NEUROBLASTOMA; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVIEW; SARCOMA; SURVIVAL RATE;

CHILD; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; EUROPE; HUMANS; LEGISLATION, DRUG; NEOPLASMS; OFF-LABEL USE;

EID: 77953026387     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.02.008     Document Type: Review

References (43)

1. Pearson A.D., Pinkerton C.R., Lewis I.J., Imeson J., Ellershaw C., Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008, 9:247-256.
2. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a children's oncology group phase 1 study. Blood 2004, 104:2655-2660.
3. Zwaan C.M., Den Boer M.L., Beverloo H.B., et al. Dasatinib (SPRYCEL) in children and adolescents with relapsed or refractory leukemia: preliminary results of the CA180018 phase I/II study. Blood 2006, 108:613a.
4. Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
5. Pulsipher M.A. Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?. Pediatr Blood Cancer 2004, 43:523-533.
6. Kolb E.A., Gorlick R., Houghton P.J., et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:1190-1197.
7. Attias D., Weitzman S. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Curr Opin Pediatr 2008, 20:17-22.
8. Raetz E.A., Cairo M.S., Borowitz M.J., et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a children's oncology group pilot study. J Clin Oncol 2008, 26:3756-3762.
9. Zwaan C.M., Reinhardt D., Corbacioglu S., et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate use basis. Blood 2003, 101:3868-3871.
10. Janoueix-Lerosey I., Lequin D., Brugieres L., et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970.
11. Rossler J., Geoerger B., Taylor M., Vassal G. Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors. Curr Cancer Drug Targets 2008, 8:76-85.
12. Taussig H.B. Thalidomide and phocomelia. Pediatrics 1962, 30:654-659.
13. Chintagumpala M., Blaney S.M., Bomgaars L.R., et al. Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol 2004, 22:4394-4400.
14. Mulhern R.K., Kepner J.L., Thomas P.R., Armstrong F.D., Friedman H.S., Kun L.E. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a pediatric oncology group study. J Clin Oncol 1998, 16:1723-1728.
15. Fitter S., Dewar A.L., Kostakis P., et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008, 111:2538-2547.
16. Glade Bender J.L., Adamson P.C., Reid J.M., et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children's oncology group study. J Clin Oncol 2008, 26:399-405.
17. Breitkreutz J., Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv 2007, 4:37-45.
18. Taylor J.A., Winter L., Geyer L.J., Hawkins D.S. Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia. Cancer 2006, 107:1400-1406.
19. Cohen M.H., Johnson J.R., Massie T., et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res 2006, 12:5329-5335.
20. Lee D.P., Skolnik J.M., Adamson P.C. Pediatric phase I trials in oncology: an analysis of study conduct efficiency. J Clin Oncol 2005, 23:8431-8441.
21. Pieters R., Schrappe M., De Lorenzo P., et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007, 370:240-250.
22. Vassal G., Michel G., Esperou H., et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008, 61:113-123.
23. Pieters R., Appel I., Kuehnel H.J., et al. Pharmacokinetics, pharmacodynamics, efficacy and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia - a randomized phase II clinical trial. Blood 2008, 112:4832-4838.
24. Panetta J.C., Iacono L.C., Adamson P.C., Stewart C.F. The importance of pharmacokinetic limited sampling models for childhood cancer drug development. Clin Cancer Res 2003, 9:5068-5077.
25. Panetta J.C., Kirstein M.N., Gajjar A., et al. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol 2003, 52:435-441.
26. Georger B, Morland B, Ndiaye A, et al. Target-driven explaoratory study of imatinib mesylate in children with solid malignancies by the innovative therapies for children with cancer (ITCC) European consortium. Eur J Cancer, 2009, April 9, E-pub ahead of print.
27. Boos J. Off label use - label off use?. Ann Oncol 2003, 14:1-5.
28. Hirschfeld S., Ho P.T., Smith M., Pazdur R. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. J Clin Oncol 2003, 21:1066-1073.
29. Hirschfeld S., Shapiro A., Dagher R., Pazdur R. Pediatric oncology: regulatory initiatives. Oncologist 2000, 5:441-444.
30. Vassal G., Giammarile F., Brooks M., et al. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Societe Francaise d'Oncologie Pediatrique (SFOP) and the United Kingdom children cancer study group (UKCCSG). Eur J Cancer 2008, 44:2453-2460.
31. Vassal G., Couanet D., Stockdale E., et al. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French society of pediatric oncology and the United Kingdom children's cancer study group. J Clin Oncol 2007, 25:356-361.
32. Wagner-Bohn A., Ripkens-Reinhard A., Benninger-Doring G., Boos J. Implementing good clinical practice in two noncommercial phase II studies in children with cancer. Onkologie 2007, 30:21-26.
33. Geoerger B., Gaspar N., Opolon P., et al. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int J Cancer 2008, 123:209-216.
34. Houghton P.J., Morton C.L., Tucker C., et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007, 49:928-940.
35. Neale G., Su X., Morton C.L., et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008, 14:4572-4583.
36. Kolb E.A., Gorlick R., Houghton P.J., et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:1198-1206.
37. Holleman A., Cheok M.H., Den Boer M.L., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004, 351:533-542.
38. Hulleman E, Kazemier KM, Holleman A, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood, 2008, E-pub ahead of print.
39. Levis M., Brown P., Smith B.D., et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006, 108:3477-3483.
40. Verschuur A., Zwaan C.M. Nederland kan niet achterblijven. Fase-I-onderzoek noodzaak voor kinderen met kanker. Medisch Contact 2007, 62:909-912.
41. Goemans B.F., Zwaan C., Miller M., et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005, 19:1536-1542.
42. Stone R.M. Targeted agents in AML: much more to do. Best Pract Res Clin Haematol 2007, 20:39-48.
43. Stone R.M., De Angelo D.J., Galinsky I., et al. PKC412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol 2004, 83(Suppl. 1):89-90.